Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Epithalon (Epitalon): Telomere & Longevity Peptide Research Guide

Back to library
peptide

Epithalon (Epitalon): Telomere & Longevity Peptide Research Guide

11 min read
RESEARCH GUIDE
LONGEVITY RESEARCH
TELOMERE BIOLOGY
EPITHALON PEPTIDE
✅ RESEARCH CHEMICAL

Research Use Only. Epithalon is sold strictly as a research chemical for in vitro and laboratory study. This article summarises published preclinical research literature. It does not constitute medical advice, a treatment protocol, or a recommendation for human use. No claims are made regarding life extension or anti-aging effects in humans.

Epithalon (also written Epitalon; IUPAC: L-alanyl-L-α-glutamyl-L-aspartyl-glycine; CAS: 307297-39-8; MW: 390.35 Da) is a synthetic tetrapeptide representing the defined active component of Epithalamin — a polypeptide extract from the bovine pineal gland that showed lifespan-extending properties in Soviet gerontology research dating to the 1970s. The translation from complex extract to defined four-amino-acid sequence — Ala-Glu-Asp-Gly — was accomplished by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, producing one of the most studied longevity peptides in the preclinical biology literature. This guide covers the compound’s origin, mechanisms, research evidence, and current evidentiary limitations.

Key Takeaways

  • Epithalon: Ala-Glu-Asp-Gly tetrapeptide (CAS: 307297-39-8, MW: 390.35 Da) — derived from bovine pineal Epithalamin extract; Khavinson group synthesis
  • Primary mechanism: telomerase (hTERT) activation → telomere elongation → extended replicative lifespan in somatic cell models
  • Secondary mechanisms: melatonin synthesis upregulation in the pineal gland, SOD/antioxidant enzyme activation, reduced oxidative DNA damage
  • Rodent lifespan studies: 14–35% extension in SHR rats and CBA mice; reduced spontaneous tumour incidence in some cohorts
  • Critical limitation: almost all published data originates from the Khavinson group — independent replication is largely absent
  • No completed human RCT for longevity or telomere endpoints; human safety profile based on Russian clinical experience with Epithalamin extract
4
Amino Acids
Ala-Glu-Asp-Gly
390.35
Daltons (MW)
CAS: 307297-39-8
35%
Max Lifespan Extension
Rodent models (Khavinson)
1980s
Origin Research
St. Petersburg Institute

Research-grade Epithalon from Pure Grade Labs — supplied with full CoA, HPLC purity data, and QR-authenticated documentation.

View Research Catalogue →

Origin: From Pineal Extract to Defined Tetrapeptide

The pineal gland — a small endocrine structure in the dorsal forebrain — has been associated with lifespan regulation since the early neuroendocrinology work of Walter Pierpaoli in the 1990s and, decades earlier, Soviet gerontology researchers investigating the relationship between hypothalamic-pituitary ageing and longevity. The mechanism proposed was that pineal-derived factors (primarily melatonin, but also undefined peptide fractions) regulate the “biological clock” governing ageing rate.

Khavinson’s group isolated Epithalamin from bovine pineal tissue in the 1970s–80s and demonstrated in multiple rodent cohorts that repeated injection or feeding of the extract produced measurable lifespan extension compared to untreated controls. The active fraction was a complex polypeptide mixture — not a defined molecule. The translation to a defined structure required systematic fractionation and bioassay-guided peptide identification over approximately two decades of work, eventually yielding the tetrapeptide Ala-Glu-Asp-Gly as the minimal active structure retaining the full biological activity of the parent extract.

The synthetic tetrapeptide form — Epithalon — was first described in peer-reviewed form in 2002–2003 with the publication of the telomerase activation data. It has since been the subject of >50 publications, virtually all from the Khavinson group and collaborating Russian institutions.

Telomerase Activation: The hTERT Mechanism

The defining mechanistic claim for Epithalon is activation of telomerase — specifically the catalytic reverse transcriptase subunit hTERT (human Telomerase Reverse Transcriptase), which adds TTAGGG repeat sequences to telomere ends to counteract replication-associated shortening.

In normal somatic cells, the hTERT gene is epigenetically repressed — silenced by promoter methylation and histone deacetylation after early embryogenesis. Without telomerase activity, telomeres shorten by approximately 50–200 base pairs per cell division. After 40–60 divisions (the Hayflick limit), telomeres reach a critically short length that triggers the DNA damage response, p53 activation, and either cellular senescence (permanent cell cycle arrest) or apoptosis.

Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine 135(6):590–592; PMID: 12937682) reported that Epithalon treatment of cultured human somatic cells:

  • Induced detectable telomerase activity (measured by TRAP assay — Telomere Repeat Amplification Protocol) in cells that previously showed undetectable telomerase
  • Produced measurable telomere elongation after multiple passages in Epithalon-treated versus control cultures
  • Extended the number of cell divisions before senescence onset in fetal fibroblast lines

The proposed molecular mechanism for how a four-amino-acid peptide reactivates the epigenetically silenced hTERT gene is not fully characterised. Khavinson’s group has proposed that the AEDG tetrapeptide sequence interacts with chromatin-regulating proteins to reduce promoter methylation or modify histone marks at the hTERT locus — a form of direct epigenetic reprogramming by a short peptide. This mechanism, while plausible in principle (several short peptides are known to interact with DNA-binding proteins), has not been confirmed by independent chromatin immunoprecipitation or DNA methylation sequencing data.

Research Context — The Nobel Prize Connection: The 2009 Nobel Prize in Physiology or Medicine was awarded to Elizabeth Blackburn, Carol Greider, and Jack Szostak for the discovery of telomeres and telomerase. Their foundational work — establishing that telomeres protect chromosomes from degradation and that telomerase maintains their length — created the molecular biology framework within which all telomerase-activating compounds (including Epithalon) are now interpreted. Blackburn’s subsequent work on telomere length as a biomarker of biological ageing and disease risk transformed telomere research from an esoteric molecular biology question into a clinical priority. Epithalon research, while predating the Nobel Prize work in its origins, gained significantly broader scientific credibility as telomere biology became mainstream. The fact that telomere shortening is now firmly established as a hallmark of biological ageing means Epithalon’s proposed hTERT activation mechanism sits within a robust theoretical framework — the mechanism is biologically meaningful even if the specific Epithalon data requires independent replication.

Secondary Mechanisms: Melatonin Synthesis and Pineal Function

Beyond telomerase activation, Epithalon has been studied for its effects on the pineal gland — its tissue of origin — and specifically on melatonin synthesis. The pineal gland’s melatonin production declines significantly with age: young adults produce peak nocturnal melatonin of 80–150 pg/mL; by age 70, this often falls below 30 pg/mL. This age-associated melatonin decline has been proposed as a contributor to circadian disruption, reduced antioxidant capacity, and altered immune function in elderly populations.

Preclinical studies from the Khavinson group report that Epithalon administration to aged rats increases both pineal melatonin synthesis and nocturnal melatonin plasma levels, potentially restoring a more youthful circadian hormone profile. The proposed mechanism is that Epithalon acts as a trophic signal on ageing pinealocytes — stimulating the hydroxyindole-O-methyltransferase (HIOMT) enzyme involved in the final melatonin synthesis step.

The importance of this effect in the longevity research context is that melatonin itself has extensive preclinical evidence for antioxidant activity, mitochondrial protective effects, and lifespan extension in animal models — meaning Epithalon-driven melatonin restoration could contribute to its observed lifespan effects independently of its telomerase activity.

Antioxidant and DNA Protection Research

Reactive oxygen species (ROS) are a primary driver of telomere shortening — oxidative damage to the TTAGGG repeat sequence is repaired more slowly than damage to the internal coding genome, making telomeres disproportionately vulnerable to oxidative stress. Any intervention that reduces oxidative burden therefore indirectly protects telomere integrity.

Epithalon studies have reported:

  • Increased superoxide dismutase (SOD) and catalase activity in the liver, brain, and blood of aged rodents treated with Epithalon — reducing superoxide and hydrogen peroxide accumulation
  • Reduced levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG) — a biomarker of oxidative DNA damage — in the liver of treated animals versus age-matched controls
  • Reduced lipid peroxidation (TBARS assay) in multiple tissues, consistent with systemic antioxidant enhancement

These antioxidant findings potentially explain part of the tumour-inhibitory effect reported in some Epithalon lifespan studies: reduced oxidative DNA damage lowers the rate of somatic mutation accumulation that drives oncogenesis. If confirmed independently, this would represent a mechanistic pathway by which Epithalon simultaneously reduces two risks that increase with ageing — telomere attrition and carcinogenesis — without the theoretical cancer-promoting risk of constitutive telomerase activation.

Animal Lifespan Studies: The Rodent Evidence

The most attention-grabbing data in the Epithalon literature involves rodent lifespan extension. Across several published studies using different strains and treatment protocols, the Khavinson group reported:

Study / Model Treatment Lifespan Effect Other Findings
CBA mice (Anisimov 2003) Epithalon SC, lifelong +27% mean, +35% max ↓ spontaneous tumour incidence
SHR rats (Khavinson 2002) Epithalon IP, 6 months +14% mean lifespan Improved immune parameters
HER-2/neu transgenic mice (Anisimov 2002) Epithalon SC, lifelong Lifespan extended ↓ mammary tumour growth rate
Fruit fly (Drosophila) (Khavinson 2011) Epithalon in medium +11–16% mean lifespan Reduced age-related locomotor decline

Critical assessment: These results are striking — if reproducible in independent laboratories, they would represent among the strongest data for any pharmacological lifespan intervention in mammals. However, the absence of replication from independent groups is a major evidential limitation. The lifespan studies were conducted at the St. Petersburg Institute using protocols that have not been published with sufficient methodological detail for complete assessment. No independent laboratory has published a replication of the rodent lifespan data using Epithalon as of 2025.

Research-grade Epithalon from Pure Grade Labs — batch-verified with HPLC purity data for qualified research.

Browse Research Chemicals →

Research Context — The Independent Replication Problem in Longevity Research: Epithalon is not unique in facing this challenge. The longevity research field has historically struggled with replication: caloric restriction lifespan effects in rodents failed to fully translate to primates in some NIA-sponsored studies; resveratrol lifespan extension in yeast and nematodes did not replicate robustly in mammals; rapamycin results have replicated better but with complex trade-offs in immune function. The Epithalon data exists in a research ecosystem where (a) most of the output originates from one group, (b) independent funding for replication is scarce, and (c) the mechanism (telomerase epigenetic reactivation by a tetrapeptide) is genuinely novel and would require significant validation investment to confirm. This does not make the data false — it makes it appropriately preliminary. Researchers approaching Epithalon should treat the published data as a strong hypothesis generating enough mechanistic plausibility to warrant independent investigation, not as established fact.

Sourcing and Purity Considerations for Epithalon Research

Epithalon analytical characterisation should confirm: MW of 390.35 Da by ESI-MS (a small, well-resolved tetrapeptide — straightforward to confirm by mass spectrometry), RP-HPLC purity ≥98%, and correct amino acid sequence Ala-Glu-Asp-Gly. As a tetrapeptide, Epithalon has excellent chemical stability in lyophilised form compared to larger peptides — shelf life at −20°C of 2+ years is achievable with appropriate storage conditions.

The most common quality issue in Epithalon sourcing is sequence errors in synthesis or incomplete deprotection of side-chain protecting groups (particularly for the Asp and Glu residues). Mass spec confirmation is the only reliable way to exclude these issues. Pure Grade Labs Epithalon is supplied with HPLC and MS verification data as standard.

Frequently Asked Questions

What is the difference between Epithalon and Epitalon?

Epithalon and Epitalon are two spellings of the same compound (Ala-Glu-Asp-Gly; CAS: 307297-39-8). “Epithalon” is the most common English spelling in the research literature; “Epitalon” appears in some publications and supplier catalogues. There is no structural difference — both names refer to the identical synthetic tetrapeptide.

How does Epithalon activate telomerase?

The proposed mechanism is epigenetic: Epithalon is hypothesised to interact with chromatin-associated proteins to reduce promoter methylation or modify histone modifications at the hTERT locus, thereby re-expressing the silenced telomerase gene. This mechanism has not been confirmed by independent chromatin immunoprecipitation or bisulphite sequencing. The telomerase activity (TRAP assay) and telomere elongation findings have been published but await independent replication.

Is there a cancer risk from activating telomerase?

Constitutive telomerase activation is a feature of most cancer cells — this is the theoretical concern with telomerase-activating interventions. Importantly, the Khavinson rodent studies reported reduced tumour incidence in Epithalon-treated cohorts — the opposite of what a cancer-promoting effect would produce. The proposed explanation is that restoring telomerase in normal senescing cells (which are at high oncogenic risk due to genomic instability from short telomeres) may reduce cancer risk rather than increase it. This requires independent verification.

What is the research evidence quality for Epithalon?

Mechanistically interesting but limited in independent validation. The telomerase, antioxidant, and rodent lifespan data originate almost entirely from the Khavinson group — a single research institution. The absence of independent replication is the primary evidence quality limitation. The mechanistic plausibility (telomere biology is a well-established ageing hallmark) is high; the empirical confidence in the Epithalon-specific data requires independent verification to achieve broad scientific acceptance.

Summary

Epithalon (Epitalon) occupies a unique position in longevity research: a structurally simple four-amino-acid peptide with mechanistically plausible claims (telomerase activation, antioxidant enhancement, melatonin restoration) and preclinical lifespan data that, if independently verified, would represent among the strongest pharmacological longevity interventions studied in mammals. The limitation is single-group provenance — almost all published data derives from Khavinson’s St. Petersburg institute, and independent replication is the critical missing piece. For researchers with institutional access and interest in telomere biology, Epithalon provides a mechanistically coherent study target with published protocols and a defined chemical identity that makes experimental design straightforward.

Source research-grade Epithalon from Pure Grade Labs — with MS-verified purity documentation.

Shop Research Chemicals →

References

  1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. PMID: 12937682
  2. Anisimov VN, Khavinson VKh, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7–10. PMID: 12360209
  3. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193–202. PMID: 14501183
  4. Khavinson VKh, Goncharova ND, Lapin BA. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinol Lett. 2001;22(4):251–254. PMID: 11524632
  5. Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350(6265):1193–1198. PMID: 26785477
  6. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. PMID: 23746838

Disclaimer: This article is published for educational and research purposes only. Epithalon is sold by Pure Grade Labs strictly as a research chemical, not for human consumption or therapeutic use. No claims are made regarding life extension, anti-aging effects, or telomere lengthening in humans. All research use must comply with applicable institutional and regulatory requirements.